Summary by Moomoo AI
Invivyd reported its first commercial revenue of $25.4M from PEMGARDA sales in 2024, while narrowing its net loss to $169.9M from $198.6M in 2023. The loss per share improved to $1.43 from $1.81 YoY, with R&D expenses remaining stable at $99.8M compared to $102.0M in 2023. The company maintained a cash position of $69.3M as of December 31, 2024.The company's operational focus centered on PEMGARDA commercialization and VYD2311 development, with VYD2311 program expenses significantly increasing to $67.5M from $1.4M in 2023. Meanwhile, Pemivibart program expenses decreased to $31.8M from $96.7M YoY. Strategic partnerships remained crucial, including ongoing collaboration with Adimab for antibody technology, involving $1.0M in royalty payments and a $2.0M annual platform transfer fee.The company operates as a single segment focused on monoclonal antibody research, development, and commercialization, particularly targeting immunocompromised patients. Federal NOL carryforwards increased to $392.0M from $318.6M in 2023, with additional state NOL carryforwards of $249.3M. The company maintained a full valuation allowance against deferred tax assets, resulting in a 0% effective tax rate.
Comment(0)
Reason For Report